As incidence rates for lung cancer are still very high and lung cancer remains the most deadly cancer since the turn of the millennium, efforts have been made to find new approaches in cancer research. This systematic review highlights how therapeutic options were extended and how the development of new drugs has picked up speed during the last 20 years.

A systematic search was performed in PubMed, Cochrane Library and the European Union Trial Register and 443 records were identified. Our inclusion criteria constituted completed phase I, II and III studies investigating drugs approved by the European Medicines Agency (EMA). Overall, 127 articles were analysed.

During the 5 year interval from 2015 to 2020, significantly more drugs were approved after phase III, and occasionally after phase II, trials than between 2000 and 2005 (p=0.002). Furthermore, there was a significant time difference (p=0.00001) indicating an increasingly briefer time interval between the publication of phase I and phase III results in the last few years.

Due to novel therapeutic approaches, numerous new drugs in lung oncology were approved. This has improved symptoms and prognoses in patients with advanced lung cancer. However, faster approval could make it difficult to scrutinise new options regarding safety and efficacy with sufficient diligence.

由于肺癌的发病率仍然很高，并且肺癌仍然是新世纪以来最致命的癌症，因此人们努力寻找癌症研究的新方法。这篇系统综述重点介绍了过去 20 年中治疗选择的扩展方式以及新药的开发速度如何加快。

在 PubMed、Cochrane 图书馆和欧盟试验注册库中进行了系统搜索，确定了 443 条记录。我们的纳入标准构成了调查欧洲药品管理局 (EMA) 批准的药物的已完成的 I、II 和 III 期研究。总共分析了 127 篇文章。

在 2015 年至 2020 年的 5 年时间间隔内，与 2000 年至 2005 年相比，在 III 期试验后批准的药物明显更多，偶尔在 II 期试验后获批 (p=0.002)。此外，存在显着的时间差异 (p=0.00001)，表明在过去几年中 I 期和 III 期结果发布之间的时间间隔越来越短。

由于新的治疗方法，许多肺肿瘤新药获得批准。这改善了晚期肺癌患者的症状和预后。然而，更快的批准可能会导致难以以足够的勤奋审查有关安全性和有效性的新选择。